Enrico Garaci

This inventor holds 14 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 10 EPO patents. Top assignees: Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., Istituto Superiore Di Sanita, Sciclone Pharmaceuticals International, Ltd.. Active years: 2001-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Enrico Garaci. Retrieved from https://idiyas.com/inventor/enrico-garaci

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 6)

% Patents Active = 57.1

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 3.2

ph-index = 2

Forward Citations = 11(Granted Patents)

Company Filing History:

3 out of 343

Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.

patents

2 out of 26

Istituto Superiore Di Sanita

patents

2 out of 4

Sciclone Pharmaceuticals International, Ltd.

patents

4. 2 out of 21

Sciclone Pharmaceuticals, Inc.

patents

5. 1 out of 325

Consiglio Nazionale Delle Ricerche

Sciclone Pharmaceuticals International (Sg) Pte. Ltd.

patents

8. 1 out of 24

Università Degli Studi Di Firenze

patents

9. 2 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12083165 - Thymosin alpha 1 for use in treatment of cystic fibrosis (2024-09-10),

2. 11524056 - Thymosin alpha 1 for use in treatment of cystic fibrosis (2022-12-13),

3. 10478474 - Thymosin alpha 1 for use in treatment of cystic fibrosis (2019-11-19),

4. 10214591 - Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject (2019-02-26),

5. 9150627 - Anti tumoral immunogenic peptides and vaccine thereof (2015-10-06),

6. 8785493 - Treatment of retroviral reservoirs exploiting oxidative stress (2014-07-22),

7. 8445484 - Bicyclic peptidomimetic inhibitors of aspartyl-proteases for the treatment of infectious diseases (2013-05-21),

8. 8431617 - Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections (2013-04-30),

9. 8389680 - [object Object] (2013-03-05),

10. 8337828 - Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection (2012-12-25),

11. 8207294 - [object Object] (2012-06-26),

12. 8022036 - Use of thymosin alpha 1 for the treatment of immunological diseases (2011-09-20),

13. 7625892 - Pharmaceutical compositions for the treatment of diseases related to neurotrophines (2009-12-01),

14. 6180681 - 2-cyclopenten-1-one as an inducer of HSP70 (2001-01-30),

Title: Enrico Garaci: Innovator in Cystic Fibrosis Treatment

Introduction

Enrico Garaci, based in Rome, Italy, is a distinguished inventor with a remarkable portfolio of 14 patents. His contributions to the medical field, particularly in the treatment of cystic fibrosis, showcase his innovative spirit and commitment to advancing healthcare solutions.

Latest Patents

Among his latest patents, two notable innovations stand out. Both concern Thymosin alpha 1 (Tα1) for use in the treatment of cystic fibrosis, serving as a CFTR corrector, CFTR potentiator, and anti-inflammatory agent. These inventions represent significant advancements in the ongoing battle against cystic fibrosis, providing new avenues for therapeutic intervention.

Career Highlights

Throughout his career, Garaci has made substantial strides in pharmaceutical innovations. He has worked with renowned companies such as Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. and Sciclone Pharmaceuticals International, Ltd. His experience with these organizations has undoubtedly enriched his expertise and has allowed him to contribute meaningfully to the development of novel treatments.

Collaborations

Collaboration has been a key aspect of Garaci’s work. He has teamed up with fellow experts like Luigina Romani and Francesco Bistoni, pooling their knowledge and skills to enhance research and innovation in medical treatments. Such partnerships exemplify the collaborative spirit essential for groundbreaking inventions.

Conclusion

Enrico Garaci continues to be a leading figure in the realm of medical invention. His patents and collaborations play a vital role in the pursuit of effective therapies for cystic fibrosis, and his ongoing contributions represent a beacon of hope for many affected by this challenging condition. With a robust foundation of innovation, Garaci's work will undoubtedly pave the way for future advancements in healthcare.

Profile summary based on public USPTO records.